The cancer cells could be celled biomass without normal cellular regulation. They bypass most of the signaling pathways leading to programmed cell division. On the other hand, the embryos are highly regulated, giving rise to the whole organism based on the planned regulation. Understanding the bridge concepts between them might be an interventional art for discovering valuable cancer drugs. The present review highlighted the most similarities between them and recent literary works.
Citation: Kishore Kumar Meenakshi Sundaram, Giridharan Bupesh, Konda Mani Saravanan. Instrumentals behind embryo and cancer: a platform for prospective future in cancer research[J]. AIMS Molecular Science, 2022, 9(1): 25-45. doi: 10.3934/molsci.2022002
[1] | Yanlin Li, A. A. Abdel-Salam, M. Khalifa Saad . Primitivoids of curves in Minkowski plane. AIMS Mathematics, 2023, 8(1): 2386-2406. doi: 10.3934/math.2023123 |
[2] | Jiafan Zhang, Xingxing Lv . On the primitive roots and the generalized Golomb's conjecture. AIMS Mathematics, 2020, 5(6): 5654-5663. doi: 10.3934/math.2020361 |
[3] | Lilan Dai, Yunnan Li . Primitive decompositions of idempotents of the group algebras of dihedral groups and generalized quaternion groups. AIMS Mathematics, 2024, 9(10): 28150-28169. doi: 10.3934/math.20241365 |
[4] | Anthony Overmars, Lorenzo Ntogramatzidis, Sitalakshmi Venkatraman . A new approach to generate all Pythagorean triples. AIMS Mathematics, 2019, 4(2): 242-253. doi: 10.3934/math.2019.2.242 |
[5] | Jiafan Zhang, Xingxing Lv . Correction: On the primitive roots and the generalized Golomb's conjecture. AIMS Mathematics, 2022, 7(5): 8607-8608. doi: 10.3934/math.2022480 |
[6] | Wenpeng Zhang, Tingting Wang . The primitive roots and a problem related to the Golomb conjecture. AIMS Mathematics, 2020, 5(4): 3899-3905. doi: 10.3934/math.2020252 |
[7] | Yaguo Guo, Shilin Yang . Projective class rings of a kind of category of Yetter-Drinfeld modules. AIMS Mathematics, 2023, 8(5): 10997-11014. doi: 10.3934/math.2023557 |
[8] | Guoqing Wang . A generalization of Kruyswijk-Olson theorem on Davenport constant in commutative semigroups. AIMS Mathematics, 2020, 5(4): 2992-3001. doi: 10.3934/math.2020193 |
[9] | Shahida Bashir, Ahmad N. Al-Kenani, Maria Arif, Rabia Mazhar . A new method to evaluate regular ternary semigroups in multi-polar fuzzy environment. AIMS Mathematics, 2022, 7(7): 12241-12263. doi: 10.3934/math.2022680 |
[10] | Ze Gu, Xiang-Yun Xie, Jian Tang . On C-ideals and the basis of an ordered semigroup. AIMS Mathematics, 2020, 5(4): 3783-3790. doi: 10.3934/math.2020245 |
The cancer cells could be celled biomass without normal cellular regulation. They bypass most of the signaling pathways leading to programmed cell division. On the other hand, the embryos are highly regulated, giving rise to the whole organism based on the planned regulation. Understanding the bridge concepts between them might be an interventional art for discovering valuable cancer drugs. The present review highlighted the most similarities between them and recent literary works.
Primitive semigroups have been an important topic of semigroup researches since the 1950s. In fact, as early as 1954, Preston who is one of the founders of the algebraic theory of semigroups studied primitive inverse semigroups in [16], and then he gave the characterization of primitive regular semigroups and applied it to the study of matrix representations of inverse semigroups in [17]. In particular, he pointed out that a regular semigroup (resp. an inverse semigroup) with zero is primitive if and only if it is the 0-direct union of a family of completely 0-simple semigroups (resp. Brandt semigroups) (See also the monographs [5,12,18]). In addition, from the view of category Lawson [12] showed that an inverse semigroup with zero is primitive if and only if it is isomorphic to a groupoid with zero adjoined. On the other hand, Theorem Ⅲ.3.5 and Corollary Ⅲ.3.6 in [5] together give that a regular semigroup (resp. an inverse semigroup) without zero is primitive if and only if it is a completely simple semigroup (resp. a group). Furthermore, primitive orthodox semigroups were also concerned in Venkatesan [21].
As generalizations of regular semigroups, abundant semigroups were introduced and investigated in 1982 by Fountain in [2] where the class of primitive abundant semigroups and its several subclasses, such as primitive abundant semigroups with regularity condition, primitive quasi-adequate semigroups and primitive adequate semigroups etc., were also characterized. We observe that the roles of quasi-adequate semigroups and adequate semigroups in the range of abundant semigroups are similar to those of orthodox semigroups and inverse semigroups in the range of regular semigroups, respectively.
In 1991, Lawson [13] went a further step to generalize abundant semigroups to U-semiabundant semigroups where U is a nonempty subset of the set of idempotents and correspondingly generalize quasi-adequate semigroups and adequate semigroups to weakly U-orthodox semigroups and Ehresmann semigroups, respectively. The class of Ehresmann semigroups and its special subclasses (for example, the class of restriction semigroups) now form a hot research topic, and a lot of achievements in this line have been obtained by many semigroup experts, for example, see [3,4,6,8,10,11,13,20] and the references therein. In particular, Gould [3,4] gave the equivalent definition of Ehresmann semigroups from the view of variety, and Jones explicitly introduced the notion of primitive Ehresmann semigroups in [8] and by using small categories obtained a construction of primitive Ehresmann semigroups with zero in [10] which is analogous to that of primitive inverse semigroups with zero given in Lawson [12] by using groupoids. We also observe that Lawson [14] investigated a class of primitive U-semiabundant semigroups named Rees semigroups and Wang [22] characterized primitive weakly U-orthodox semigroups, which generalize the corresponding results of primitive abundant semigroups provided in [2].
On the other hand, Jones [7] generalized Ehresmann semigroups to P-Ehresmann semigroups from a varietal perspective and provided a common framework for Ehresmann semigroups and regular *-semigroups. Regular *-semigroups first appeared in Nordahl and Scheiblich [15] and a generalization of this class of semigroups was investigated in the author [23]. For more details for regular ∗-semigroups, the reader may consult the texts[1,7,15,19,23] and their references. At present, some valuable results have been obtained on P-Ehresmann semigroups. For instance, the constructions of P-Ehresmann semigroups have been considered by "fundamental approach" in [7] and [25,26] by "categorical approach", respectively. Variety properties, semigroup algebras and completions of P-Ehresmann semigroups have been explored in Jones [8], Wang [24] and Yan and Wang [27], respectively.
From the above discussions, the following problem is natural: How to introduce and characterize primitive P-Ehresmann semigroups? The aim of this paper is to solve the above problem. We have introduced the notion of projection-primitive P-Ehresmann semigroups and established the structures of projection-primitive P-Ehresmann semigroups. In particular, we show that projection-primitive P-Ehresmann semigroups are always P-restriction. Our work may be regarded as extending primitive Ehresmann semigroups introduced and investigated by Jones in [8] and [10], respectively.
In this section, after recalling some necessary notions and results on P-Ehresmann semigroups, we shall introduce projection-primitive P-Ehresmann semigroups and explore their basic properties.
For a semigroup S, we always denote the set of idempotents in S by E(S). From Lemma 2.2 and its dual in Gould [3], a bi-unary semigroup (S,⋅,+,∗) is called an Ehresmann semigroup if the following identities hold:
x+x=x,(xy)+=(xy+)+,(x+y+)+=x+y+,x+y+=y+x+,(x+)∗=x+ |
xx∗=x,(xy)∗=(x∗y)∗,(x∗y∗)∗=x∗y∗,x∗y∗=y∗x∗,(x∗)+=x∗. |
To extend Ehresmann semigroups, P-Ehresmann semigroups were introduced in Jones [7] from the view of variety. A bi-unary semigroup (S,⋅,+,∗) is called a P-Ehresmann semigroup if the following identities hold:
![]() |
A P-Ehresmann semigroup (S,⋅,+,∗) is called P-restriction if
(xy)+x=xy+x∗ and x(yx)∗=x+y∗x for all x,y∈S. |
In a P-Ehresmann semigroup (S,⋅,+,∗), the set of projections is PS={a+∣a∈S} which is equal to {a∗∣a∈S} by (ⅴ) and (ⅴ)′. The following lemmas collect some basic properties of P-Ehresmann semigroups first given in Jones [7].
Lemma 2.1 ([7]). A bi-unary semigroup (S,⋅,+,∗) is Ehresmann (resp. restriction) if and only if (S,⋅,+,∗) is P-Ehresmann (resp. P-restriction) and PS is a subsemilattice of S.
Lemma 2.2 ([7]). Let (S,⋅,+,∗) be a P-Ehresmann semigroup and x,y∈S,e,f∈PS.
(1) (x+y)+=x+y+x+,x++=x+,x+(xy)+x+=(xy)+.
(2) (xy∗)∗=y∗x∗y∗,x∗∗=x∗,y∗(xy)∗y∗=(xy)∗.
(3) (ef)2=ef,e+=e=e∗,(ef)+=efe=(fe)∗∈PS.
(4) ef∈PS if and only if ef=fe.
Let (S,⋅,+,∗) be a P-Ehresmann semigroup. Define a relation on PS by the rule
e≤fifandonlyife=ef=feforalle,f∈PS. |
Then it is easy to see that ≤ is a partial order on PS. By Lemma 2.2, the following corollary is obvious.
Corollary 2.3. Let (S,⋅,+,∗) be a P-Ehresmann semigroup and x,y∈S,e,f∈PS. Then (xy)+≤x+,(xy)∗≤y∗ and efe≤e.
Similar to the case of restriction semigroups appeared in Jones [8], we call a P-Ehresmann semigroup (S,⋅,+,∗) without zero or with zero 0 satisfying 0∉PS projection-primitive if
(∀e,f∈PS)e≤f⟹e=f, |
while call a P-Ehresmann semigroup (S,⋅,+,∗) with zero 0 satisfying 0∈PS projection-primitive if
(∀e,f∈PS)e≤f⟹e=0ore=f. |
Observe that a primitive Ehresmann semigroup without zero is just a momoid in which the identity is the only projection by Lemma 2.1. We first characterize projection-primitive P-Ehresmann semigroups without zero.
Proposition 2.4. Let (S,⋅,+,∗) be a P-Ehresmann semigroup without zero. Then the following statements are equivalent:
(1) S is projection-primitive.
(2) (xy)+=x+ for all x,y∈S.
(3) (xy)∗=y∗ for all x,y∈S.
Proof. We only show that (1) is equivalent to (2), and one can prove that (1) is equivalent to (3) by similar arguments. If S is projection-primitive and x,y∈S, then (xy)+≤x+ by Corollary 2.3. This implies that (xy)+=x+. Conversely, let e,f∈PS and e≤f. Then ef=fe=e. By the given condition and Lemma 2.2, we have f=f+=(fe)+=e+=e. This gives the projection-primitivity of S.
From Jones [9], a P-Ehresmann semigroup (S,⋅,+,∗) is called reduced if PS contains exactly one element. By the identities (ⅰ) and (ⅰ)′, in this case S is a monoid with the only projection as its identity. Obviously, reduced P-Ehresmann semigroups are always projection-primitive. In fact, we have the following result.
Proposition 2.5. Let (S,⋅,+,∗) be a P-Ehresmann semigroup with zero 0 and 0∉PS. Then the following statements are equivalent:
(1) S is projection-primitive.
(2) x+=0+ for all x∈S.
(3) x∗=0∗ for all x∈S.
In this case, S is a reduced P-Ehresmann semigroup with the identity 0+ and so is an Ehresmann semigroup.
Proof. We only show that (1) is equivalent to (2), and one can prove that (1) is equivalent to (3) by similar arguments. Let S be projection-primitive and x∈S. Then 0+=(x0)+≤x+ by Corollary 2.3, and so 0+=x+. Conversely, the given condition (2) implies that PS={x+∣x∈S}={0+}. This gives that S is reduced and has identity 0+, and so is projection-primitive certainly.
Remark 2.6. By Proposition 2.5, a projection-primitive P-Ehresmann (or Ehresmann) semigroup (S,⋅,+,∗) with zero 0 and 0∉PS is reduced and is exactly a monoid with zero containing at least two elements.
Now we consider projection-primitive P-Ehresmann semigroups with zero 0 as a projection.
Proposition 2.7. Let (S,⋅,+,∗) be a projection-primitive P-Ehresmann semigroup with zero 0 and 0∈PS.
(1) For all x∈S, x+=0⟺x=0⟺x∗=0.
(2) For all x,y∈S∖{0}, xy≠0⟺x∗y+x∗=x∗⟺y+x∗y+=y+.
Proof. (1) Let x∈S. We only prove that x+=0 if and only if x=0. The other equivalence can be showed by symmetry. In fact, if x+=0, then x=x+x=0x=0 by (ⅰ). To show the converse, we first observe that 0+=(a0)+≤a+ for all a∈S by Corollary 2.3. This implies that 0+ is the minimum element in PS. Since 0∈PS, it follows that 0+=0+0=0.
(2) Let x,y∈S∖{0}. We only prove that xy≠0 if and only if x∗y+x∗=x∗. The other equivalence can be showed by symmetry. If xy≠0, then xx∗y+y=xy≠0 by the identities (ⅰ) and (ⅰ)′. This implies that x∗≠0 and x∗y+≠0. By item (1) we have x∗+≠0 and (x∗y+)+≠0. But Corollary 2.3 gives that (x∗y+)+≤x∗+, and so (x∗y+)+=x∗+ by the projection-primitivity of S. Moreover, Lemma 2.2 provides that x∗y+x∗=(x∗y+)+=x∗+=x∗. Conversely, if x∗y+x∗=x∗, then by using (ⅱ), (ⅰ)′, (ⅱ), Lemma 2.2 (3), (ⅰ)′ and item (1) of the present lemma in order, we have
(xy)+=(xy+)+=(xx∗y+)+=(x(x∗y+)+)+=(xx∗y+x∗)+=(xx∗)+=x+≠0, | (2.1) |
which implies that xy≠0 by item (1) of the present lemma again. To end this section, we observe the following interesting result.
Theorem 2.8. A projection-primitive P-Ehresmann semigroup is always P-restriction.
Proof. Let (S,⋅,+,∗) be a projection-primitive P-Ehresmann semigroup and x,y∈S. Firstly, if S contains no zero, then (xy)+x=x+x=x by Proposition 2.4. By Corollary 2.3, we have x∗y+x∗≤x∗, and so x∗y+x∗=x∗ by the projection-primitivity of S. This implies that xy+x∗=xx∗y+x∗=xx∗=x by (ⅰ)′. Thus (xy)+x=xy+x∗. Dually, we have x(yx)∗=x+y∗x. Secondly, if S contains a zero 0 and 0∉PS, then it is obvious that (xy)+x=xy+x∗ and x(yx)∗=x+y∗x by Proposition 2.5. Finally, assume that S contains a zero 0 and 0∈PS. If xy=0, then by Proposition 2.7 (1) and (ⅱ) we have 0=(xy)+=(xy+)+ and xy+=0. This implies that (xy)+x=0=xy+x∗. If xy≠0, then (xy)+≠0 and x∗=x∗y+x∗ by Proposition 2.7. Since (xy)+≤x+ by Corollary 2.3, the projection-primitivity of S gives that (xy)+=x+. This implies that
xy+x∗=xx∗y+x∗=xx∗=x=x+x=(xy)+x |
by (ⅰ) and (ⅰ)′. Therefore, (xy)+x=xy+x∗. Dually, we have x(yx)∗=x+y∗x. Thus, S is P-restriction in all cases.
In the remainder of this paper, we shall establish the structures of projection-primitive P-Ehresmann semigroups. The present section is devoted to projection-primitive P-Ehresmann semigroups without zero or with zero which is not a projection. The following theorem characterize these semigroups completely.
Theorem 3.1. Let I and Λ be two sets and ϕ:I→Λ,i↦iϕ be a bijection. Assume that M is a monoid, |I×M×Λ|≠1 and P=(pλi)Λ×I is a Λ×I-matrix over M satisfying piϕ,i=e=piϕ,jpjϕ,i for all i,j∈I, where e is the identity of M. Define a binary and two unary operations on the set
S=M(I,Λ,M,P)={(i,x,λ)∣i∈I,x∈M,λ∈Λ} |
as follows:
(i,x,λ)(j,y,μ)=(i,xpλjy,μ),(i,x,λ)+=(i,e,iϕ),(i,x,λ)∗=(λϕ−1,e,λ). |
Then (S,⋅,+,∗) is a projection-primitive P-Ehresmann semigroup without zero or with zero which is not a projection. Conversely, every such semigroup can be obtained in this way.
Proof. Direct part. By hypothesis, S0 can be regarded as a Rees matrix semigroup over the monoid M0. Denote P(S0)={(i,p−1λi,λ)∣i∈I,λ∈Λ}∪{0} and U={(i,e,iϕ)∣i∈I}. Then by Proposition 1.5 in Lawson [14], we can easily show that for all (i,x,λ),(j,y,μ)∈S,
(i,x,λ)˜RP(S0)(j,y,μ)⟺(i,x,λ)˜RU(j,y,μ)⟺i=j, |
(i,x,λ)˜LP(S0)(j,y,μ)⟺(i,x,λ)˜LU(j,y,μ)⟺λ=μ. |
Moreover, ˜RU (resp. ˜LU) is a left congruence (resp. a right congruence) on S by Lemma 1.9 in Lawson [14]. By the given condition on the matrix P, it is easy to see that U is both a right projection-set and a left projection-set of S in the sense of Jones [7] (see page 629). According to Theorem 6.1 of Jones [7] and its dual, (S,⋅,+,∗) is a P-Ehresmann semigroup and PS=U. Moreover, in view of Proposition 1.7 of Lawson [14], no two different elements in PS can be compatible. Thus S is projection-primitive. If (i,z,λ) is the zero element of S, then for all (j,y,μ)∈S, we have (i,z,λ)(j,y,μ)=(i,z,λ)=(j,y,μ)(i,z,λ). This implies that i=j and λ=μ. In this case, |I|=|Λ|=1 and so PS contains only one element. By hypothesis, S has at least two elements and so the zero is not a projection.
Converse part. Let (M,⋅,+,∗) be a projection-primitive P-Ehresmann semigroup with zero which is not a projection. Then by Proposition 2.5 and Remark 2.6, M has at least two elements and is a monoid with the only projection e as its identity. In this case, M has the form in the theorem certainly.
Now let (T,⋅,+,∗) be a projection-primitive P-Ehresmann semigroup without zero. Then it is easy to see that T0 is a Rees semigroup with respect to U=P0T in the sense of Lawson [14], and ˜LU={(a,b)∈T0×T0∣a∗=b∗}∪{(0,0)} and ˜RU={(a,b)∈T0×T0∣a+=b+}∪{(0,0)} (see page 28 in [14]). Fix an element e∈PT and denote I={xe∣x∈PT},Λ={ex∣x∈PT}. Define ϕ:I→Λ,xe↦ex for all x∈PT. Then ϕ is a bijection. In fact, if x,y∈PT and xe=ye, then x=x+=(xe)+=(ye)+=y+=y by Lemma 2.2 and Proposition 2.4, and so ex=ey. This fact and its dual give that ϕ is bijection. We assert that piϕ,i=e=piϕ,jpjϕ,i for all i,j∈I. In fact, take i=xe,j=ye∈I where x,y∈PT. Then iϕ=ex and jϕ=ey. This implies by Lemma 2.2 and Proposition 2.4 that piϕ,i=(iϕ)i=(ex)(xe)=exe=(ex)+=e+=e and
piϕ,jpjϕ,i=((iϕ)j)((jϕ)i)=exyeeyxe=exyeyxe=(e(xyeyx))+=e+=e. |
On the other hand, for every t∈T, we have (t+e)+=t+ and (et∗)∗=t∗ by Proposition 2.4. In view of Lemma 2.2 (4), I and Λ can index the non-zero ˜RU-classes and ˜LU-classes of T0, respectively. Denote M={a∈T∣a+=a∗=e}∪{0}. For i∈I and λ∈Λ, let ri=i and qλ=λ and denote pλi=qλri=λi. Since (t+e)+=t+, (et∗)∗=t∗, (ete)+=(ete)∗=e and t=(t+e)ete(et∗) by Lemma 2.2 and Proposition 2.4, in view of the proof of Theorem 3.6 in Lawson [14],
θ:T0→S=M0(I,Λ,M,P),t↦(t+e,ete,et∗),0↦0 |
is a semigroup isomorphism. Moreover, if we define
(i,a,λ)+=(i,e,iϕ),(i,a,λ)∗=(λϕ−1,e,λ),0+=0∗=0 |
on S, then we can see that θ also preserves + and ∗ by Lemma 2.2 and Proposition 2.4. By the construction of P=(pλi), θ|T is a (2,1,1)-isomorphism from T onto M(I,Λ,M,P).
In Theorem 3.1, if we identify i with iϕ for all i∈I, we can assume that I=Λ. So we have the following corollary.
Corollary 3.2. Let I be a set and M a monoid with |I×M|≠1. Assume that P=(pλi)I×I is an I×I-matrix over M satisfying pii=e=pijpj,i for all i,j∈I, where e is the identity of M. Define a binary and two unary operations on the set
S=M(I,M,P)={(i,x,j)∣i,j∈I,x∈M} |
as follows:
(i,x,j)(k,y,l)=(i,xpjky,l),(i,x,j)+=(i,e,i),(i,x,j)∗=(j,e,j). |
Then (S,⋅,+,∗) is a projection-primitive P-Ehresmann semigroup without zero or with zero which is not a projection. Conversely, every such semigroup can be obtained in this way.
In this section, we consider the structures of projection-primitive P-Ehresmann semigroups with zero as a projection. To this aim, we need to recall some necessary notions and results. From Jones [7], a left projection algebra consists of a nonempty set P and a binary operation "×" satisfying the following axioms:
(P1) e×e=e.
(P2) e×(e×f)=(e×f)×e=e×f.
(P3) (e×f)×g=e×(f×(e×g)).
(P4) e×(f×g)=(e×f)×(e×(f×g)).
For simplicity, we use the words "projection algebra" to replace "left projection algebra" in the sequel. Let (P,×) be a projection algebra. Define a relation "≤P" on P by the rule that for all e,f∈P, e≤Pfifandonlyife=f×e. Then ≤P is a partial order on P by (P1)–(P4). Moreover, by (P2) it is easy to see that
e×f≤Pe | (4.1) |
for all e,f∈P. A projection algebra (P,×) with the least element 0 with respect to ≤P is called primitive if no two different elements in P∖{0} can be compatible. On primitive projection algebras, we have the following simple results.
Proposition 4.1. A primitive projection algebra (P,×) is just a (2, 0)-type algebra (P,×,0) satisfying the following conditions: For all e,f∈P,
(Pr1) e×e=e.
(Pr2) 0×e=0=e×0.
(Pr3) e×f=0ore×f=e.
(Pr4) e×f=0ifandonlyiff×e=0.
In particular, if e×f=f×e for all e,f∈P, then e×f≠0 if and only if e=f≠0.
Proof. Let (P,×) be a primitive projection algebra with the least element 0. We only need to show that (Pr2)–(Pr4) hold. Let e,f∈P. Since 0≤Pe, we have e×0=0, and so 0×e=(e×0)×e=e×0=0 by (P2). This proves (Pr2). In view of (4.1), (Pr3) is true. Finally, if e×f=0 and f×e≠0, then f×e=f≠0 by (Pr3). However,
f×e=(f×e)×e=f×(e×(f×e))=f×(e×f)=f×0=0 |
by (P3) and (Pr2). This is a contradiction. So (Pr4) holds.
Conversely, let (P,×,0) be a (2, 0)-type algebra satisfying the given conditions. We only need to show that (P2)–(P4) hold. Let e,f,g∈P. By (Pr3), e×f=0 or e×f=e. In the former case, all items in (P2) are equal to 0 by (Pr2). In the latter case, all items in (P2) are equal to e by (Pr1). This shows (P2). Moreover, we also have e×g=0 or e×g=e. Then the following four cases may occur:
(1)e×f=e,e×g=e;(2)e×f=e,e×g=0;(3)e×f=0,e×g=e;(4)e×f=0,e×g=0. |
In case (1), (e×f)×g=e×g=e and e×(f×(e×g))=e×(f×e). By (Pr3) and (Pr4), f×e=f in the case. So e×(f×e)=e×f=e. This proves (P3) for case (1). The other cases can be showed similarly. Finally, we consider (P4). By (Pr3), f×g=f or f×g=0. In the former case, the left side of (P4) is e×f, the right side of (P4) is (e×f)×(e×f)=e×f by (Pr1), and so they are equal. In the latter case, the two sides of (P4) are both 0 by (Pr2). The final result of the proposition follows from (Pr1), (Pr3) and (Pr4).
By the dual of Proposition 2.4 in [7], and Propositions 2.7 and 4.1, we have the following result easily.
Lemma 4.2. Let (S,⋅,+,∗) be a primitive P-Ehresmann semigroup with zero 0 and 0∈PS. Define a binary operation "×S" on PS as follows: For all e,f∈PS, e×Sf=(ef)+=efe. Then (PS,×S,0) forms a primitive projection algebra. In particular, if S is Ehresmann, then e×Sf=f×Se for all e,f∈PS by Lemma 2.1.
Let C be a nonempty set with a partial binary operation ⋅ and (P,×,0) a primitive projection algebra with (P∖{0})⊆C. Assume that d:C→P,x↦d(x), r:C→P,x↦r(x) are maps such that d(C)∪r(C)⊆(P∖{0}) and
d(e)=e=r(e) | (4.2) |
for all e∈(P∖{0}). According to Wang [26], C=(C,⋅,d,r,P) is called a generalized category over (P,×,0) if the following conditions hold:
(G1) For all x,y∈C, x⋅y is defined if and only if r(x)×d(y)≠0 and then d(x⋅y)=d(x) and r(x⋅y)=r(y).
(G2) If x,y,z∈C such that both x⋅y and y⋅z are defined, then (x⋅y)⋅z=x⋅(y⋅z).
(G3) For all x∈C, d(x)⋅x and x⋅r(x) are defined and d(x)⋅x=x=x⋅r(x).
(G4) If e,f∈P and e×f≠0, then (e⋅f)⋅e=e.
If e×f=f×e for all e,f∈P, then e×f≠0 if and only if e=f, and so (G4) is always satisfied by (4.2), (G3) and Proposition 4.1. In this case, C=(C,⋅,d,r,P) is a category in usual sense.
Proposition 4.3. Let C=(C,⋅,d,r,P) be a generalized category over the primitive projection algebra (P,×,0). Put C0=C∪{0}. Define a binary operation on C0 as follows: If x,y∈C and x⋅y is defined in C, then xy=x⋅y; all other products in C0 are 0. Moreover, define two unary operations on C0 as follows: 0♣=0♠=0 and x♣=d(x),x♠=r(x) for all x∈C. With these operations C0 is a projection-primitive P-Ehresmann semigroup with 0 as a projection. In the sequel, we call (C0,⋅,♣,♠) a generalized category with zero adjoined.
Proof. Let x,y,z∈C0. It is routine to check that (xy)z=0 precisely when x(yz)=0. Thus C0 is a semigroup by (G2). We shall show that the identities (ⅰ)–(ⅴ) and (ⅰ)′–(ⅴ)′ are satisfied. Let x,y∈C0. If 0∈{x,y}, the identities (ⅰ)–(ⅴ) and (ⅰ)′–(ⅴ)′ are satisfied obviously. So we assume that x,y∈C. Firstly, since d(x)⋅x=x by (G3), we have x♣x=x. This gives (ⅰ). Dully, we have (ⅰ)′. Secondly, since d(y♣)=d(d(y))=d(y) by (4.2), it follows that xy♣≠0 if and only if xy≠0 by (G1). If this is the case, we have
(xy♣)♣=d(xy♣)=d(x)=d(xy)=(xy)♣ |
by (G1) again. This is exactly the identity (ⅱ). Dually, (ⅱ)′ is also true. Thirdly, by (4.2), (G1) and (Pr4), we can see that
x♣y♣≠0⟺d(x)×d(y)≠0⟺x♣y♣x♣≠0. |
In this case, we have
(x♣y♣)♣=d(d(x)d(y))=d(d(x))=d(x) |
by (G1) and x♣y♣x♣=d(x)d(y)d(x)=d(x) by (G4). This implies that the identity (ⅲ) is true. Dually, (ⅲ)′ is valid. Moreover, by (4.2), (G1) and (G3) we have
x♣x♣=d(x)d(x)=d(d(x))d(x)=d(x). |
This gives (ⅳ). Similarly, we have (ⅳ)′. The identities (ⅴ) and (ⅴ)′ follow from the fact (x♣)♠=r(d(x))=d(x)=x♣ by (4.2) and its dual. We have shown that (C0,⋅,♣,♠) is a P-Ehresmann semigroup with the set of projections
PC0={x♣∣x∈C0}=P={d(x)∣x∈C}∪{0}={r(x)∣x∈C}∪{0}. |
Finally, let e,f∈PC0 and e≤f. Then e=ef=fe. If e≠0, then f⋅e is defined and so e=d(e)=d(fe)=d(f)=f by (4.2) and (G1). Thus, (C0,⋅,♣,♠) is projection-primitive.
Remark 4.4. Let C=(C,⋅,d,r,P) be a generalized category over the primitive projection algebra (P,×,0). If P contains at least three elements and e×f≠0 for all e,f∈P∖{0}, then x⋅y is defined for all x,y∈C. By Propositions 4.3 and 2.5, (C,⋅,♣,♠) is a projection-primitive P-Ehresmann semigroup without zero. On the other hand, if P contains two elements, say, P={0,1}, then (C,⋅,♣,♠) is a reduced P-Ehresmann semigroup. In fact, (C,⋅) is a monoid with 1 as identity, and (C0,⋅) is a monoid with zero adjoined. Thus we can think that generalized categories with zero adjoined covers the semigroups considered in the last section.
Now we can give the main result of this section, which is a generalization of a result on restriction semigroups obtained by Jones in Section 4 of [10].
Theorem 4.5. Let (S,⋅,+,∗) be a P-Ehresmann semigroup with zero as a projection and |S|>1. Then S is projection-primitive if and only if S is (2, 1, 1)-isomorphic to a generalized category with zero adjoined.
Proof. We have proved in Proposition 4.3 that every generalized category with zero adjoined is a projection-primitive P-Ehresmann semigroup with zero as a projection. To prove the converse, let (S,⋅,+,∗) be a projection-primitive P-Ehresmann semigroup with zero 0 and 0∈PS. By Lemma 4.2, (PS,×S,0) forms a primitive projection algebra. Denote C=S∖{0}. Define a partial binary operation "⋅" as follows:
x⋅y={xyif xy≠0,undefinedif xy=0, | (4.3) |
where xy denotes the multiplication of x and y in the semigroup S. Define maps
d:C→PS,x↦x+, r:C→PS,x↦x∗. | (4.4) |
Then we have d(C)∪r(C)⊆(PS∖{0}) by Proposition 2.7 (1), and d(e)=e=r(e) for all e∈PS∖{0} by Lemma 2.2, respectively.
We assert that (C,⋅,d,r,PS) is a generalized category over the primitive projection algebra (PS,×S,0). First, let x,y∈C. By Proposition 2.7 (2) and (Pr3), (Pr4),
x⋅yisdefined⟺x∗y+x∗=x∗ |
⟺y+x∗y+=y+⟺r(x)×Sd(y)≠0⟺d(y)×Sr(x)≠0. |
In this case, by the identities defining P-Ehresmann semigroups and Lemma 2.2 we have
d(x⋅y)=d(xy)=(xy)+=(xy+)+=(xx∗y+)+ |
=(x(x∗y+)+)+=(xx∗y+x∗)+=(xx∗)+=x+=d(x). |
Dually, we have r(x⋅y)=r(y). Thus (G1) holds. Next, let x,y,z∈C, and x⋅y and y⋅z be defined. Since r(x⋅y)=r(y) and d(y⋅z)=d(y), (x⋅y)⋅z and x⋅(y⋅z) are defined, and so (x⋅y)⋅z=(xy)z=x(yz)=x⋅(y⋅z). This gives (G2). Moreover, for x∈C, since x+x=x≠0, it follows that x+⋅x is defined and d(x)⋅x=x. Dually, x⋅x∗ is defined and x⋅r(x)=x. Thus (G3) is true. Finally, let e,f∈PS and e×Sf≠0. Then f×Se≠0 by (Pr4) and e=e×Sf=efe by (Pr3). In view of (G2), (e⋅f)⋅e is defined and (e⋅f)⋅e=(ef)e=efe=e. Thus (G4) is valid.
By Proposition 4.3, we have a generalized category with zero adjoined (C0,⋅,♣,♠). We shall show that S is (2, 1, 1)-isomorphic to C0. Define a map ψ:S→C0 by assigning 0ψ=0 and xψ=x for all x∈C=S∖{0}. Obviously, ψ is a bijection. Let x,y∈S. If x=0 or y=0, then xψ=0 or yψ=0, whence (xy)ψ=0ψ=0=(xψ)(yψ). Assume that x,y∈C=S∖{0}. Then xy=0 in (S,⋅,+,∗) if and only if x⋅y is not defined in the generalized category (C,⋅,d,r,PS), if and only if xy=0 in (C0,⋅,♣,♠) by (4.3) and Proposition 4.3. This implies that (xy)ψ=(xψ)(yψ) for all x,y∈C. Thus ψ is a semigroup homomorphism. Furthermore, observe that 0+=0 by Proposition 2.7 (1) and 0♣=0 by Proposition 4.3, it follows that (0ψ)♣=0♣=0=0ψ=0+ψ. Dually, we have (0ψ)♠=0∗ψ. If x∈C=S∖{0}, then x+∈C by Proposition 2.7 (1), this implies that (xψ)♣=x♣=d(x)=x+=x+ψ by Propositions 4.3 and (4.4). Dually, we have (xψ)♠=x∗ψ for all x∈C. We have shown that ψ is a (2, 1, 1)-isomorphism. By Lemma 4.2 and the statements before Proposition 4.3, we have the following result appeared in Jones [10].
Corollary 4.6 ([10]). Let (S,⋅,+,∗) be an Ehresmann semigroup with zero as a projection and |S|>1. Then S is projection-primitive if and only if S is (2, 1, 1)-isomorphic to a category with zero adjoined.
Remark 4.7. Let (S,⋅,+,∗) be a primitive P-Ehresmann semigroup without zero or with zero 0 but 0∉PS. Let ⋄∉S and define additionally x⋄=⋄x=⋄=⋄⋄ and ⋄+=⋄∗=⋄. Then (S⋄,⋅,+,∗) forms a primitive P-Ehresmann semigroup with zero ⋄ and ⋄∈PS⋄. In this case, the generalized category associated with S⋄ constructed in the proof of Theorem 4.5 is just (S,⋅,+,∗) and the corresponding generalized category with zero adjoined is just (S⋄,⋅,+,∗). By Remark 4.4, we can think that Theorem 4.5 also works for the semigroups considered in the last section. However, it is trivial certainly in the case.
In this paper, we have obtained the structures of projection-primitive P-Ehresmann semigroups. As a future work, one can investigate the associative algebras of these semigroups by using the results obtained in the present paper.
The author expresses his profound gratitude to the referees for the valuable comments and suggestions, which improve greatly the content and presentation of this article. In particular, according to the advices of one of the referees, we rewrite Section 3 (with the help of the results of Lawson [14] provided by the referee) and Section 4. This research is supported by the National Natural Science Foundation of China (11661082). Thanks also go to the editor for the timely communications.
The author declares there is no conflict of interest.
[1] |
Blagosklonny MV (2005) Teratogens as anti-cancer drugs. Cell Cycle 4: 1518-1521. https://doi.org/10.4161/cc.4.11.2208 ![]() |
[2] |
Ramazani M, Jaktaji RP, Shirazi FH, et al. (2019) Analysis of apoptosis related genes in nurses exposed to anti-neoplastic drugs. BMC Pharmacol Toxicol 20. https://doi.org/10.1186/s40360-019-0372-0 ![]() |
[3] |
Finnell RH (1999) Teratology: general considerations and principles. J Allergy Clin Immunol 103: S337-S342. https://doi.org/10.1016/S0091-6749(99)70259-9 ![]() |
[4] |
Vargesson N (2015) Thalidomide-induced teratogenesis: History and mechanisms. Birth Defects Res Part C Embryo Today Rev 105: 140-156. https://doi.org/10.1002/bdrc.21096 ![]() |
[5] |
Coyle I, Wayner MJ, Singer G (1976) Behavioral teratogenesis: A critical evaluation. Pharmacol Biochem Behav 4: 191-200. https://doi.org/10.1016/0091-3057(76)90014-9 ![]() |
[6] |
Flaxman SM, Sherman PW (2000) Morning sickness: a mechanism for protecting mother and embryo. Q Rev Biol 75: 113-148. https://doi.org/10.1086/393377 ![]() |
[7] |
Mei N, Guo X, Ren Z, et al. (2017) Review of Ginkgo biloba-induced toxicity, from experimental studies to human case reports. J Environ Sci Heal Part C 35: 1-28. https://doi.org/10.1080/10590501.2016.1278298 ![]() |
[8] |
Wu C-P, Ohnuma S, V Ambudkar S (2011) Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12: 609-620. https://doi.org/10.2174/138920111795163887 ![]() |
[9] |
Sung H, Ferlay J, Siegel RL, et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71: 209-249. https://doi.org/10.3322/caac.21660 ![]() |
[10] | Roy M, Datta A (2019) Cancer: Types and Hallmarks. Cancer Genetics and Therapeutics.Springer 1-26. https://doi.org/10.1007/978-981-13-9471-3_1 |
[11] |
Manzo G (2019) Similarities Between Embryo Development and Cancer Process Suggest New Strategies for Research and Therapy of Tumors: A New Point of View. Front cell Dev Biol 7: 20. https://doi.org/10.3389/fcell.2019.00020 ![]() |
[12] |
Shabo I, Svanvik J, Lindström A, et al. (2020) Roles of cell fusion, hybridization and polyploid cell formation in cancer metastasis. World J Clin Oncol 11: 121. https://doi.org/10.5306/wjco.v11.i3.121 ![]() |
[13] |
Ledbetter DH (2009) Chaos in the embryo. Nat Med 15: 490-491. https://doi.org/10.1038/nm0509-490 ![]() |
[14] | Erenpreisa J, Giuliani A (2020) Resolution of Complex Issues in Genome Regulation and Cancer Requires Non-Linear and Network-Based Thermodynamics. Int J Mol Sci 21. https://doi.org/10.3390/ijms21010240 |
[15] | Erenpreisa J, Salmina K, Anatskaya O, et al. (2020) Paradoxes of cancer: Survival at the brink. Semin Cancer Biol . https://doi.org/10.1016/j.semcancer.2020.12.009 |
[16] | Krebs ET (1947) CANCER AND THE EMBRYONAL HYPOTHESIS. Calif Med 66: 270-271. |
[17] |
Saitoh M (2018) Involvement of partial EMT in cancer progression. J Biochem 164: 257-264. https://doi.org/10.1093/jb/mvy047 ![]() |
[18] |
Saitoh M (2018) JB special review-cellular plasticity in epithelial homeostasis and diseases: Involvement of partial EMT in cancer progression. J Biochem 164: 257-264. https://doi.org/10.1093/jb/mvy047 ![]() |
[19] |
Mukund K, Syulyukina N, Ramamoorthy S, et al. (2020) Right and left-sided colon cancers-specificity of molecular mechanisms in tumorigenesis and progression. BMC Cancer 20. https://doi.org/10.1186/s12885-020-06784-7 ![]() |
[20] |
Wessely A, Steeb T, Berking C, et al. (2021) How neural crest transcription factors contribute to melanoma heterogeneity, cellular plasticity, and treatment resistance. Int J Mol Sci 22. https://doi.org/10.3390/ijms22115761 ![]() |
[21] |
Saravanan KM, Kannan M, Meera P, et al. (2022) E3 ligases: a potential multi-drug target for different types of cancers and neurological disorders. Future Med Chem 14: 187-201. https://doi.org/10.4155/fmc-2021-0157 ![]() |
[22] |
Ben-Porath I, Thomson MW, Carey VJ, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507. https://doi.org/10.1038/ng.127 ![]() |
[23] |
Viswanathan A, Musa A, Murugesan A, et al. (2019) Battling Glioblastoma: A Novel Tyrosine Kinase Inhibitor with Multi-Dimensional Anti-Tumor Effect (Running Title: Cancer Cells Death Signalling Activation). Cells 8. https://doi.org/10.3390/cells8121624 ![]() |
[24] | Doan P, Nguyen P, Murugesan A, et al. (2021) Targeting orphan g protein-coupled receptor 17 with t0 ligand impairs glioblastoma growth. Cancers (Basel) 13. https://doi.org/10.3390/cancers13153773 |
[25] |
Cofre J, Abdelhay E (2017) Cancer Is to Embryology as Mutation Is to Genetics: Hypothesis of the Cancer as Embryological Phenomenon. ScientificWorldJournal 2017: 3578090. https://doi.org/10.1155/2017/3578090 ![]() |
[26] |
Rountree CB, Mishra L, Willenbring H (2012) Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology 55: 298-306. https://doi.org/10.1002/hep.24762 ![]() |
[27] |
Qin S, Jiang J, Lu Y, et al. (2020) Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduct Target Ther 5: 228. https://doi.org/10.1038/s41392-020-00313-5 ![]() |
[28] | Pierce GB (1983) The cancer cell and its control by the embryo. Rous-Whipple Award lecture. Am J Pathol 113: 117. |
[29] |
Liu J (2018) The dualistic origin of human tumors. Semin Cancer Biol 53: 1-16. https://doi.org/10.1016/j.semcancer.2018.07.004 ![]() |
[30] |
Xu B, Konze KD, Jin J, et al. (2015) Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp Hematol 43: 698-712. https://doi.org/10.1016/j.exphem.2015.05.001 ![]() |
[31] |
Wang W, Qin J, Voruganti S, et al. (2015) Polycomb group (PcG) proteins and human cancers: multifaceted functions and therapeutic implications. Med Res Rev 35: 1220-1267. https://doi.org/10.1002/med.21358 ![]() |
[32] |
Murray MJ, Lessey BA (1999) Embryo implantation and tumor metastasis: Common pathways of invasion and angiogenesis. Semin Reprod Endocrinol 17: 275-290. https://doi.org/10.1055/s-2007-1016235 ![]() |
[33] |
Costanzo V, Bardelli A, Siena S, et al. (2018) Exploring the links between cancer and placenta development. Open Biol 8: 180081. https://doi.org/10.1098/rsob.180081 ![]() |
[34] |
Turajlic S, Sottoriva A, Graham T, et al. (2019) Resolving genetic heterogeneity in cancer. Nat Rev Genet 20: 404-416. https://doi.org/10.1038/s41576-019-0114-6 ![]() |
[35] | Wagner GP, Kshitiz, Dighe A, et al. (2021) The Coevolution of Placentation and Cancer. Annu Rev Anim Biosci 10. https://doi.org/10.1146/annurev-animal-020420-031544 |
[36] |
Fukuda MN, Sugihara K (2008) An integrated view of L-selectin and trophinin function in human embryo implantation. J Obstet Gynaecol Res 34: 129-136. https://doi.org/10.1111/j.1447-0756.2008.00776.x ![]() |
[37] |
Ayala GE, Dai H, Li R, et al. (2006) Bystin in perineural invasion of prostate cancer. Prostate 66: 266-272. https://doi.org/10.1002/pros.20323 ![]() |
[38] |
Aplin JD, Ruane PT (2017) Embryo–epithelium interactions during implantation at a glance. J Cell Sci 130: 15-22. https://doi.org/10.1242/jcs.175943 ![]() |
[39] |
Harada O, Suga T, Suzuki T, et al. (2007) The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer. Int J Cancer 121: 1072-1078. https://doi.org/10.1002/ijc.22821 ![]() |
[40] |
Sims GP, Rowe DC, Rietdijk ST, et al. (2009) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388. https://doi.org/10.1146/annurev.immunol.021908.132603 ![]() |
[41] |
Ibrahim ZA, Armour CL, Phipps S, et al. (2013) RAGE and TLRs: relatives, friends or neighbours?. Mol Immunol 56: 739-744. https://doi.org/10.1016/j.molimm.2013.07.008 ![]() |
[42] |
Cui T, Zhang W, Li S, et al. (2019) Oxidative Stress–Induced HMGB1 Release from Melanocytes: A Paracrine Mechanism Underlying the Cutaneous Inflammation in Vitiligo. J Invest Dermatol 139: 2174-2184.e4. https://doi.org/10.1016/j.jid.2019.03.1148 ![]() |
[43] |
Rapoport BL, Steel HC, Theron AJ, et al. (2020) High Mobility Group Box 1 in Human Cancer. Cells 9. https://doi.org/10.3390/cells9071664 ![]() |
[44] | Zhang H, Li J, Saravanan KM, et al. (2021) An Integrated Deep Learning and Molecular Dynamics Simulation-Based Screening Pipeline Identifies Inhibitors of a New Cancer Drug Target TIPE2. Front Pharmacol 12. https://doi.org/10.3389/fphar.2021.772296 |
[45] |
Saravanan KM, Zhang H, Zhang H, et al. (2020) On the Conformational Dynamics of β-Amyloid Forming Peptides: A Computational Perspective. Front Bioeng Biotechnol 8. https://doi.org/10.3389/fbioe.2020.00532 ![]() |
[46] |
Viswanathan A, Kute D, Musa A, et al. (2019) 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma. Eur J Med Chem 166: 291-303. https://doi.org/10.1016/j.ejmech.2019.01.021 ![]() |
[47] |
Imashiro C, Azuma T, Itai S, et al. (2021) Travelling ultrasound promotes vasculogenesis of three-dimensional-monocultured human umbilical vein endothelial cells. Biotechnol Bioeng 118: 3760-3769. https://doi.org/10.1002/bit.27852 ![]() |
[48] | Srimathi Devi J, Haripriya D, Arul S, et al. (2021) Evaluation of anti-cancer effect of zerumbone and cisplatin on N-nitrosodiethylamine induced hepatic cancer in freshwater fish (Danio rerio). Nat Prod Res 1–5. https://doi.org/10.1080/14786419.2021.2012672 |
[49] | Saravanan KM, Ponnuraj K (2018) Sequence and structural analysis of fibronectin-binding protein reveals importance of multiple intrinsic disordered tandem repeats. J Mol Recognit : e2768. https://doi.org/10.1002/jmr.2768 |
[50] |
George EL, Georges-Labouesse EN, Patel-King RS, et al. (1993) Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119: 1079-1091. https://doi.org/10.1242/dev.119.4.1079 ![]() |
[51] | Snow CJ, Goody M, Kelly MW, et al. (2008) Time-lapse analysis and mathematical characterization elucidate novel mechanisms underlying muscle morphogenesis. PLoS Genet 4. https://doi.org/10.1371/journal.pgen.1000219 |
[52] | Murphy PA, Begum S, Hynes RO (2015) Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors. PLoS One 10. https://doi.org/10.1371/journal.pone.0120872 |
[53] | Galmiche A, Rak J, Roumenina LT, et al. (2022) Coagulome and the tumor microenvironment: an actionable interplay. Trends in Cancer . https://doi.org/10.1016/j.trecan.2021.12.008 |
[54] |
Nasser NJ, Fox J, Agbarya A (2020) Potential mechanisms of cancer-related hypercoagulability. Cancers (Basel) 12. https://doi.org/10.3390/cancers12030566 ![]() |
[55] | Yu G, Wen Q (2018) Expression of embryonic liver fodrin (ELF) and stem cell markers in CD13 liver cancer stem cells. Eur Rev Med Pharmacol Sci 22: 1653-1657. |
[56] |
Baek HJ, Lim SC, Kitisin K, et al. (2008) Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology 48: 1128-1137. https://doi.org/10.1002/hep.22460 ![]() |
[57] |
Teng B, Huang C, Cheng CL, et al. (2020) Newly identified peptide hormone inhibits intestinal fat absorption and improves NAFLD through its receptor GPRC6A. J Hepatol 73: 383-393. https://doi.org/10.1016/j.jhep.2020.02.026 ![]() |
[58] |
Bian J, Dannappel M, Wan C, et al. (2020) Transcriptional regulation of Wnt/β-catenin pathway in colorectal cancer. Cells 9: 2125. https://doi.org/10.3390/cells9092125 ![]() |
[59] |
Davis-Marcisak EF, Deshpande A, Stein-O'Brien GL, et al. (2021) From bench to bedside: Single-cell analysis for cancer immunotherapy. Cancer Cell 39: 1062-1080. https://doi.org/10.1016/j.ccell.2021.07.004 ![]() |
[60] |
Xie Y, Yao L, Yu X, et al. (2020) Action mechanisms and research methods of tRNA-derived small RNAs. Signal Transduct Target Ther 5: 1-9. https://doi.org/10.1038/s41392-020-00217-4 ![]() |
[61] |
Postovit LM, Margaryan NV, Seftor EA, et al. (2008) Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci U S A 105: 4329-4334. https://doi.org/10.1073/pnas.0800467105 ![]() |
[62] |
Dreesen O, Brivanlou AH (2007) Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 3: 7-17. https://doi.org/10.1007/s12015-007-0004-8 ![]() |
[63] |
Saravanan KM, Palanivel S, Yli-Harja O, et al. (2018) Identification of novel GPR17-agonists by structural bioinformatics and signaling activation. Int J Biol Macromol 106: 901-907. https://doi.org/10.1016/j.ijbiomac.2017.08.088 ![]() |
[64] |
Caruso S, O'Brien DR, Cleary SP, et al. (2021) Genetics of hepatocellular carcinoma: approaches to explore molecular diversity. Hepatology 73: 14-26. https://doi.org/10.1002/hep.31394 ![]() |
[65] |
Gnanavel M, Murugesan A, Mani SK, et al. (2021) Identifying the mirna signature association with aging-related senescence in glioblastoma. Int J Mol Sci 22: 1-14. https://doi.org/10.3390/ijms22020517 ![]() |
[66] |
Buhrmann C, Brockmueller A, Harsha C, et al. (2021) Evidence that tumor microenvironment initiates epithelial-to-mesenchymal transition and calebin a can suppress it in colorectal cancer cells. Front Pharmacol 12: 1689. https://doi.org/10.3389/fphar.2021.699842 ![]() |
[67] | Zhang H, Shao X, Peng Y, et al. (2019) A novel machine learning based approach for iPS progenitor cell identification. PLoS Comput Biol . https://doi.org/10.1101/744920 |
[68] |
Shetzer Y, Solomon H, Koifman G, et al. (2014) The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis 35: 1196-1208. https://doi.org/10.1093/carcin/bgu073 ![]() |
[69] | Filippi L, Pini A, Cammalleri M, et al. (2021) β3-Adrenoceptor, a novel player in the round-trip from neonatal diseases to cancer: Suggestive clues from embryo. Med Res Rev : n/a. https://doi.org/10.1002/med.21874 |
[70] |
Martinez NJ, Walhout AJM (2009) The interplay between transcription factors and microRNAs in genome-scale regulatory networks. Bioessays 31: 435-445. https://doi.org/10.1002/bies.200800212 ![]() |
[71] |
Shi G, Jin Y (2010) Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res Ther 1: 1-9. https://doi.org/10.1186/scrt39 ![]() |
[72] |
van den Berg DLC, Snoek T, Mullin NP, et al. (2010) An Oct4-centered protein interaction network in embryonic stem cells. Cell Stem Cell 6: 369-381. https://doi.org/10.1016/j.stem.2010.02.014 ![]() |
[73] |
Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10: 722-732. https://doi.org/10.1097/00001648-199911000-00013 ![]() |
[74] |
Mahendra G, Kumar S, Isayeva T, et al. (2005) Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther 12: 26-34. https://doi.org/10.1038/sj.cgt.7700754 ![]() |
[75] |
Bellamy L, Casas JP, Hingorani AD, et al. (2007) Pre-eclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. Br Med J 335: 974-977. https://doi.org/10.1136/bmj.39335.385301.BE ![]() |
[76] |
Wu P, Haththotuwa R, Kwok CS, et al. (2017) Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 10: e003497. https://doi.org/10.1161/CIRCOUTCOMES.116.003497 ![]() |
[77] |
Fong GH, Rossant J, Gertsenstein M, et al. (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70. https://doi.org/10.1038/376066a0 ![]() |
[78] | Shibuya M, Yamaguchi S, Yamane A, et al. (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely relatd to the fms family. Oncogene 5: 519-524. |
[79] |
Kim JS, Kang EJ, Woo OH, et al. (2013) The relationship between preeclampsia, pregnancy-induced hypertension and maternal risk of breast cancer: A meta-analysis. Acta Oncol (Madr) 52: 1643-1648. https://doi.org/10.3109/0284186X.2012.750033 ![]() |
[80] |
Calderon-Margalit R, Friedlander Y, Yanetz R, et al. (2009) Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study. Am J Obstet Gynecol 200: 63.e1-63.e5. https://doi.org/10.1016/j.ajog.2008.06.057 ![]() |
[81] | Yoshitomi Y, Ikeda T, Saito H, et al. (2017) JunB regulates angiogenesis and neurovascular parallel alignment in mouse embryonic skin. J Cell Sci 130: 916-926. https://doi.org/10.1242/jcs.196303 |
[82] |
Mihajlović AI, FitzHarris G (2018) Segregating chromosomes in the mammalian oocyte. Curr Biol 28: R895-R907. https://doi.org/10.1016/j.cub.2018.06.057 ![]() |
[83] |
Wang J, Batourina E, Schneider K, et al. (2018) Polyploid superficial cells that maintain the urothelial barrier are produced via incomplete cytokinesis and endoreplication. Cell Rep 25: 464-477. https://doi.org/10.1016/j.celrep.2018.09.042 ![]() |
[84] | Zhang J, Qiao Q, Xu H, et al. (2021) Human cell polyploidization: the good and the evil. Seminars in Cancer Biology.Elsevier. https://doi.org/10.1016/j.semcancer.2021.04.005 |
[85] |
Vasudevan A, Schukken KM, Sausville EL, et al. (2021) Aneuploidy as a promoter and suppressor of malignant growth. Nat Rev Cancer 21: 89-103. https://doi.org/10.1038/s41568-020-00321-1 ![]() |
[86] |
Zhu J, Tsai H-J, Gordon MR, et al. (2018) Cellular stress associated with aneuploidy. Dev Cell 44: 420-431. https://doi.org/10.1016/j.devcel.2018.02.002 ![]() |
[87] |
Vázquez-Diez C, FitzHarris G (2018) Causes and consequences of chromosome segregation error in preimplantation embryos. Reproduction 155: R63-R76. https://doi.org/10.1530/REP-17-0569 ![]() |
[88] |
Masset H, Tšuiko O, Vermeesch JR (2021) Genome-wide abnormalities in embryos: Origins and clinical consequences. Prenat Diagn 41: 554-563. https://doi.org/10.1002/pd.5895 ![]() |
[89] | Sikora E, Czarnecka-Herok J, Bojko A, et al. (2020) Therapy-induced polyploidization and senescence: Coincidence or interconnection?. Seminars in Cancer Biology.Elsevier. https://doi.org/10.1016/j.semcancer.2020.11.015 |
[90] |
Wang N, Hao F, Shi Y, et al. (2021) The Controversial Role of Polyploidy in Hepatocellular Carcinoma. Onco Targets Ther 14: 5335. https://doi.org/10.2147/OTT.S340435 ![]() |
[91] |
Amend SR, Torga G, Lin K, et al. (2019) Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance. Prostate 79: 1489-1497. https://doi.org/10.1002/pros.23877 ![]() |
[92] | Was H, Borkowska A, Olszewska A, et al. (2021) Polyploidy formation in cancer cells: How a Trojan horse is born. Seminars in Cancer Biology.Elsevier. https://doi.org/10.1016/j.semcancer.2021.03.003 |
[93] | Demin S, Berdieva M, Goodkov A, et al. (2021) Cell-cell fusions and cell-in-cell phenomena in healthy cells and cancer: Lessons from protists and invertebrates. Seminars in Cancer Biology.Elsevier. https://doi.org/10.1016/j.semcancer.2021.03.005 |
[94] |
Zack TI, Schumacher SE, Carter SL, et al. (2013) Pan-cancer patterns of somatic copy number alteration. Nat Genet 45: 1134-1140. https://doi.org/10.1038/ng.2760 ![]() |
[95] |
Chen J, Niu N, Zhang J, et al. (2019) Polyploid giant cancer cells (PGCCs): the evil roots of cancer. Curr Cancer Drug Targets 19: 360-367. https://doi.org/10.2174/1568009618666180703154233 ![]() |
[96] |
Wen Q, Goldenson B, Silver SJ, et al. (2012) Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL. Cell 150: 575-589. https://doi.org/10.1016/j.cell.2012.06.032 ![]() |
[97] |
Vakifahmetoglu H, Olsson M, Zhivotovsky B (2008) Death through a tragedy: mitotic catastrophe. Cell Death Differ 15: 1153-1162. https://doi.org/10.1038/cdd.2008.47 ![]() |
[98] |
Ganem NJ, Storchova Z, Pellman D (2007) Tetraploidy, aneuploidy and cancer. Curr Opin Genet Dev 17: 157-162. https://doi.org/10.1016/j.gde.2007.02.011 ![]() |
[99] |
Ganem NJ, Pellman D (2007) Limiting the proliferation of polyploid cells. Cell 131: 437-440. https://doi.org/10.1016/j.cell.2007.10.024 ![]() |
[100] |
Leikam C, Hufnagel AL, Otto C, et al. (2015) In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death Dis 6: e1711-e1711. https://doi.org/10.1038/cddis.2015.71 ![]() |
[101] | Zheng L, Dai H, Zhou M, et al. (2012) Polyploid cells rewire DNA damage response networks to overcome replication stress-induced barriers for tumour progression. Nat Commun 3: 1-12. https://doi.org/10.1038/ncomms1825 |
[102] |
Thura M, Ye Z, Al-Aidaroos AQ, et al. (2021) PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse. Commun Biol 4: 923. https://doi.org/10.1038/s42003-021-02449-8 ![]() |
[103] |
Liu J (2020) The “life code”: A theory that unifies the human life cycle and the origin of human tumors. Semin Cancer Biol 60: 380-397. https://doi.org/10.1016/j.semcancer.2019.09.005 ![]() |
[104] |
Niu N, Yao J, Bast RC, et al. (2021) IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis 10: 65. https://doi.org/10.1038/s41389-021-00349-4 ![]() |
[105] |
Campbell AM, Zhang Z-Y (2014) Phosphatase of regenerating liver: a novel target for cancer therapy. Expert Opin Ther Targets 18: 555-569. https://doi.org/10.1517/14728222.2014.892926 ![]() |
[106] |
Shankaranarayanan JS, Kanwar JR, AL-Juhaishi AJA, et al. (2016) Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice. Sci Rep 6: 32062. https://doi.org/10.1038/srep32062 ![]() |
[107] |
Niu N, Mercado-Uribe I, Liu J (2017) Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells. Oncogene 36: 4887-4900. https://doi.org/10.1038/onc.2017.72 ![]() |
[108] |
Xiong S, Feng Y, Cheng L (2019) Cellular reprogramming as a therapeutic target in cancer. Trends Cell Biol 29: 623-634. https://doi.org/10.1016/j.tcb.2019.05.001 ![]() |
[109] |
Labi V, Erlacher M (2015) How cell death shapes cancer. Cell Death Dis 6: e1675-e1675. https://doi.org/10.1038/cddis.2015.20 ![]() |
[110] |
Zhang D, Yang X, Yang Z, et al. (2017) Daughter Cells and Erythroid Cells Budding from PGCCs and Their Clinicopathological Significances in Colorectal Cancer. J Cancer 8: 469-478. https://doi.org/10.7150/jca.17012 ![]() |
[111] |
Zhang S, Mercado-Uribe I, Hanash S, et al. (2013) iTRAQ-based proteomic analysis of polyploid giant cancer cells and budding progeny cells reveals several distinct pathways for ovarian cancer development. PLoS One 8: e80120. https://doi.org/10.1371/journal.pone.0080120 ![]() |
[112] |
Lv H, Shi Y, Zhang L, et al. (2014) Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor. BMC Cancer 14: 576. https://doi.org/10.1186/1471-2407-14-576 ![]() |
[113] |
Xu J, Hardin H, Zhang R, et al. (2016) Stage-Specific Embryonic Antigen-1 (SSEA-1) Expression in Thyroid Tissues. Endocr Pathol 27: 271-275. https://doi.org/10.1007/s12022-016-9448-1 ![]() |
[114] |
Fleming H (2021) Opaque Polyploid Cells in Ishikawa Endometrial Cultures Are Capable of Forming Megamitochondria, Organelles Derived from the Adaptation of Fused Mitochondria Whose Capacity to Develop Gaseous Vacuoles Suggests CO2 Retention and Hypoxic Metabolism. Adv Biosci Biotechnol 12: 229-255. https://doi.org/10.4236/abb.2021.127015 ![]() |
[115] | Liu J (2021) Giant cells: Linking McClintock's heredity to early embryogenesis and tumor origin throughout millennia of evolution on Earth. Seminars in Cancer Biology.Elsevier. https://doi.org/10.1016/j.semcancer.2021.06.007 |
[116] | Liu J, Niu N, Li X, et al. (2021) The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions. Semin Cancer Biol . https://doi.org/10.1016/j.semcancer.2021.10.005 |
[117] | Li Z, Zheng M, Zhang H, et al. (2021) Arsenic Trioxide Promotes Tumor Progression by Inducing the Formation of PGCCs and Embryonic Hemoglobin in Colon Cancer Cells. Front Oncol 4046. https://doi.org/10.3389/fonc.2021.720814 |
[118] |
Jang YJ, Won JH, Back MJ, et al. (2015) Paraquat induces apoptosis through a mitochondria-dependent pathway in RAW264.7 cells. Biomol Ther 23: 407-413. https://doi.org/10.4062/biomolther.2015.075 ![]() |
[119] |
Smith DG, Sturmey RG (2013) Parallels between embryo and cancer cell metabolism. Biochem Soc Trans 41: 664-669. https://doi.org/10.1042/BST20120352 ![]() |
[120] |
Christensen DR, Calder PC, Houghton FD (2015) GLUT3 and PKM2 regulate OCT4 expression and support the hypoxic culture of human embryonic stem cells. Sci Rep 5. https://doi.org/10.1038/srep17500 ![]() |
[121] | Dang CV (2013) MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 3. https://doi.org/10.1101/cshperspect.a014217 |
[122] |
Varlakhanova NV, Cotterman RF, deVries WN, et al. (2010) Myc maintains embryonic stem cell pluripotency and self-renewal. Differentiation 80: 9-19. https://doi.org/10.1016/j.diff.2010.05.001 ![]() |
[123] |
Gabryelska A, Karuga FF, Szmyd B, et al. (2020) HIF-1α as a Mediator of Insulin Resistance, T2DM, and Its Complications: Potential Links With Obstructive Sleep Apnea. Front Physiol 11. https://doi.org/10.3389/fphys.2020.01035 ![]() |
[124] | Yu M, Lun J, Zhang H, et al. (2021) The non-canonical functions of HIF prolyl hydroxylases and their dual roles in cancer. Int J Biochem Cell Biol 135. https://doi.org/10.1016/j.biocel.2021.105982 |
[125] |
Kim J, Hong J, Lee J, et al. (2021) Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. J Control Release 332: 109-126. https://doi.org/10.1016/j.jconrel.2021.02.002 ![]() |
[126] |
Parsons MJ, Tammela T, Dow LE (2021) WNT as a driver and dependency in cancer. Cancer Discov 11: 2413-2429. https://doi.org/10.1158/2159-8290.CD-21-0190 ![]() |
[127] | Wang X, Wang Q (2018) Alpha-fetoprotein and hepatocellular carcinoma immunity. Can J Gastroenterol Hepatol 2018. https://doi.org/10.1155/2018/9049252 |
[128] |
Vujanovic L, Stahl EC, Pardee AD, et al. (2017) Tumor-derived a-fetoprotein directly drives human natural killer-cell activation and subsequent cell death. Cancer Immunol Res 5: 493-502. https://doi.org/10.1158/2326-6066.CIR-16-0216 ![]() |
[129] |
Samet JM, Avila-Tang E, Boffetta P, et al. (2009) Lung cancer in never smokers: Clinical epidemiology and environmental risk factors. Clin Cancer Res 15: 5626-5645. https://doi.org/10.1158/1078-0432.CCR-09-0376 ![]() |
[130] |
Boogerd LSF, Handgraaf HJM, Lam HD, et al. (2017) Laparoscopic detection and resection of occult liver tumors of multiple cancer types using real-time near-infrared fluorescence guidance. Surg Endosc 31: 952-961. https://doi.org/10.1007/s00464-016-5007-6 ![]() |
[131] |
Samanta S, Guru S, Elaimy AL, et al. (2018) IMP3 Stabilization of WNT5B mRNA Facilitates TAZ Activation in Breast Cancer. Cell Rep 23: 2559-2567. https://doi.org/10.1016/j.celrep.2018.04.113 ![]() |
[132] | Beilerli A, Gareev I, Beylerli O, et al. (2021) Circular RNAs as biomarkers and therapeutic targets in cancer. Seminars in Cancer Biology.Elsevier. |
[133] | Zhu T, Tu SZ, Yang YL, et al. (2019) Induced effects of resveratrol on apoptosis and autophagy in human breast cancer MDA-MB231 cells. Chinese Pharmacol Bull 35: 839-843. https://doi.org/10.1016/j.semcancer.2020.12.026 |
[134] |
Wu Y, Wang F, Albert Reece E, et al. (2015) Curcumin ameliorates high glucose-induced neural tube defects by suppressing cellular stress and apoptosis. Am J Obstet Gynecol 212: 802.e1-802.e8. https://doi.org/10.1016/j.ajog.2015.01.017 ![]() |